Avidity Biosciences Inc (NASDAQ: RNA) kicked off on Friday, down -1.12% from the previous trading day, before settling in for the closing price of $45.49. Over the past 52 weeks, RNA has traded in a range of $4.82-$48.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 148.90% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -1.53%. With a float of $100.15 million, this company’s outstanding shares have now reached $109.80 million.
In an organization with 253 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 69.4%, operating margin of -2690.64%, and the pretax margin is -2381.82%.
Avidity Biosciences Inc (RNA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Avidity Biosciences Inc is 9.59%, while institutional ownership is 99.92%. The most recent insider transaction that took place on Aug 06 ’24, was worth 1,213,822. In this transaction President and CEO of this company sold 28,000 shares at a rate of $43.35, taking the stock ownership to the 205,043 shares. Before that another transaction happened on Jul 19 ’24, when Company’s Director sold 5,000 for $45.01, making the entire transaction worth $225,069. This insider now owns 14,830 shares in total.
Avidity Biosciences Inc (RNA) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.71 earnings per share (EPS), higher than consensus estimate (set at -0.77) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.78 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.53% per share during the next fiscal year.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Take a look at Avidity Biosciences Inc’s (RNA) current performance indicators. Last quarter, stock had a quick ratio of 15.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 465.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.95, a number that is poised to hit -0.72 in the next quarter and is forecasted to reach -3.08 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.58 million. That was better than the volume of 1.33 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic%D was 67.95%. Additionally, its Average True Range was 2.86.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 85.97%, which indicates a significant increase from 75.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.94% in the past 14 days, which was higher than the 74.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $41.34, while its 200-day Moving Average is $22.75. However, in the short run, Avidity Biosciences Inc’s stock first resistance to watch stands at $45.57. Second resistance stands at $46.15. The third major resistance level sits at $46.78. If the price goes on to break the first support level at $44.36, it is likely to go to the next support level at $43.73. Assuming the price breaks the second support level, the third support level stands at $43.15.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
The company with the Market Capitalisation of 4.94 billion has total of 95,637K Shares Outstanding. Its annual sales at the moment are 9,560 K in contrast with the sum of -212,220 K annual income. Company’s last quarter sales were recorded 2,050 K and last quarter income was -70,790 K.
